Is CMS Ignoring the Realities of Biopharmaceutical Costs? | Epstein Becker & Green
On March 15, the Centers for Medicare and Medicaid Services (CMS) released guidance on the drug price negotiations provisions of the Inflation Reduction Act (IRA). The guidance contains...
Source: jdsupra.com